Foreign Powers and Investors in Costa Rica 2026
Costa Rica received $5.12B in foreign direct investment in 2025, with 54.8% from the U.S. Medical devices were the largest export. Key investors include Boston Scientific, Medtronic, Intel, and Bayer. The free-zone regime, offering tax incentives, attracted 66.4% of investments. The U.S. is the top trading and security partner, while China, the IMF, and the World Bank have narrower roles.
How this was made
The 30-second read
Why it matters
It provides concrete operational milestones (plant openings, projected investments, job targets) and a specific US tariff application timeline, but it does not deliver company-level financial guidance or earnings-impact metrics.
Market read
For traders, the actionable angle is limited to how US trade policy and operational execution risks (notably electricity reliability) may influence multinational capex and supply-chain decisions, with company-specific financial impact not quantified.
What to watch
The article flags electricity reliability and productivity gaps between free-zone and the rest of the economy, which could offset benefits from new plants and delay monetization.
Background
The piece is a country investment guide summarizing Costa Rica’s foreign direct investment, free-zone incentives, and named multinationals and lenders active in October 2026.
Ticker impact
Boston Scientific opened a third plant in Cartago on 19 May 2026, adding to Coyol and Heredia sites and 1,000 new jobs in phase one.
Likely modest positive bias as investors view incremental capacity expansion as supportive, not a near-term earnings catalyst.
The news is operational and location-specific with job counts, but no revenue, margin, or contract numbers are provided.
Medtronic opened a third manufacturing module in the Coyol free zone in November 2022 with a projected US$65 million investment.
Mild positive read-through, with limited immediate price impact absent new financial disclosures.
The article cites investment size and facility timing, but does not connect it to demand, orders, or updated guidance.
Johnson & Johnson MedTech announced a plant in Grecia in September 2023 with 3,000 jobs outside the central metropolitan area.
Neutral-to-slight positive, mainly for longer-term operational confidence.
Job creation is mentioned, but there is no investment amount, production ramp, or financial linkage.
Zimmer Biomet announced a plant in Grecia in August 2025, targeting about 500 direct jobs by 2033.
Limited near-term impact; any market reaction would likely be small and sentiment-driven.
The article provides a long-dated job target without capex, output, or financial metrics.
Intel opened its assembly and test plant in San Antonio de Belén in August 2022, and in February 2026 held a job fair tied to a transition process.
Potentially mixed, with downside risk from transition uncertainty offset by the ongoing presence of the plant.
The article signals workforce transition activity but does not specify costs, layoffs, or production changes.
Thermo Fisher Scientific is named among medical-device projects announced from 2023 to 2025 in Costa Rica.
Likely negligible immediate impact given the absence of concrete, attributable details.
Only a list inclusion is provided, with no facility, capex, or timing specifics for Thermo Fisher.
CINDE claims 18 of the world’s 35 largest medical-device multinationals operate in Costa Rica, including Abbott.
No actionable price impact expected from this claim alone.
The article explicitly labels CINDE figures as promotional and does not provide new Abbott-specific actions.
Newmont was welcomed by COMEX on 6 August 2026 for its new Global Delivery Center in a Heredia free zone, projected to reach 400 specialist jobs by end-2026.
Small positive bias at most, with limited near-term earnings relevance.
The job projection is concrete, but there is no capex, revenue, or cost impact stated.
Market effects
Highlights continued medical-device and pharma manufacturing footprint in Costa Rica, reinforcing supply-chain diversification themes for medtech and life sciences.
Emphasizes US and Switzerland as dominant investors and notes electricity reliability as a gating factor for future investment.
US tariff and semiconductor supply-chain initiatives (Pax Silica) point to broader reshoring and regionalization pressures affecting multinational capex decisions.
Counterpoint
Most company mentions are facility or promotional claims without capex-to-revenue linkage, so the trading signal may be overstated versus actual financial impact.
Key entities
- policyCosta Rica free-zone regime (Law 7210)
0% income tax for approved free-zone firms for set periods, plus exemptions and renewal rules.
- trade_policyUS tariff on certain Costa Rican goods
12.5% tariff announced by COMEX to apply from 24 July 2026, with specified exclusions.
- initiativePax Silica
US-led semiconductor and AI supply-chain initiative that Costa Rica joined in June 2026.
